# A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.

> **NCT06467370** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 342 (actual)

## Conditions studied

- Migraine

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06467370
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-02
- **Primary completion:** 2025-03-11
- **Final completion:** 2025-03-11
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06467370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06467370, "A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06467370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*